Semaglutide improves outcomes for obese patients with common skin condition, new study shows

A pioneering study, presented at the European Academy of Dermatology and Venereology (EADV) Congress 2024, demonstrates the significant potential of semaglutide in treating hidradenitis suppurative (HS), a common and chronic skin condition, in people with obesity.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup